Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia KNOXVILLE, TN, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor,...

Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent Application for Use of PV-10® Immunotherapy in Hematology KNOXVILLE, TN, April 26, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed US patent application 16/688,319,...

Provectus Announces PV-10® STING Agonist Abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II KNOXVILLE, TN, May 18, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce the publication of an abstract about and data from ongoing preclinical study of investigational...

Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...